Evaluation of VeriStrat, a serum proteomic test, in the randomized, open‐label, Phase 3 LUX‐Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second‐line treatment of advanced squamous cell carcinoma (SCC) of the lung